New aspects in vascular gene therapy

Current Opinion in Pharmacology

Volumn 10, Issue 2, 2010, Pages 208-211

  Karvinen, Henna ^a   Ylä Herttuala, Seppo ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANGIOPOIETIN 1; FIBROBLAST GROWTH FACTOR 4; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; PLACEBO; PLATELET DERIVED GROWTH FACTOR BB; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN A 165; VASCULOTROPIN B;

ANGIOGENIC GENE THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; ISCHEMIC HEART DISEASE; LIMB ISCHEMIA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; TARGET ORGAN; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; VIRUSES;

EID: 77949773080     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2010.01.004     Document Type: Review

References (21)

1. Yla-Herttuala S., Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 2003, 9:694-701.
2. Markkanen J.E., Rissanen T.T., Kivela A., Yla-Herttuala S. Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart-gene therapy. Cardiovasc Res 2005, 65:656-664.
3. Lahteenvuo J.E., Lahteenvuo M.T., Kivela A., Rosenlew C., Falkevall A., Klar J., Heikura T., Rissanen T.T., Vahakangas E., Korpisalo P., et al. Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-dependent mechanisms. Circulation 2009, 119:845-856.
4. Stewart D.J., Kutryk M.J., Fitchett D., Freeman M., Camack N., Su Y., Della S.A., Bilodeau L., Burton J.R., Proulx G., Radhakrishnan S. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther 2009, 17:1109-1115.
5. Wen S., Graf S., Massey P.G., Dichek D.A. Improved vascular gene transfer with a helper-dependent adenoviral vector. Circulation 2004, 110:1484-1491.
6. Palomeque J., Chemaly E.R., Colosi P., Wellman J.A., Zhou S., del M.F., Hajjar R.J. Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo. Gene Ther 2007, 14:989-997.
7. Raake P.W., Hinkel R., Muller S., Delker S., Kreuzpointner R., Kupatt C., Katus H.A., Kleinschmidt J.A., Boekstegers P., Muller O.J. Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors. Gene Ther 2008, 15:12-17.
8. Bish L.T., Sleeper M.M., Brainard B., Cole S., Russell N., Withnall E., Arndt J., Reynolds C., Davison E., Sanmiguel J., et al. Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines. Mol Ther 2008, 16:1953-1959.
9. Rissanen T.T., Korpisalo P., Markkanen J.E., Liimatainen T., Orden M.R., Kholova I., de Goede A., Heikura T., Grohn O.H., Yla-Herttuala S. Blood flow remodels growing vasculature during vascular endothelial growth factor gene therapy and determines between capillary arterialization and sprouting angiogenesis. Circulation 2005, 112:3937-3946.
10. Yla-Herttuala S., Rissanen T.T., Vajanto I., Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007, 49:1015-1026.
11. Korpisalo P., Karvinen H., Rissanen T.T., Kilpijoki J., Marjomaki V., Baluk P., McDonald D.M., Cao Y., Eriksson U., Alitalo K., Yla-Herttuala S. Vascular endothelial growth factor-A and platelet-derived growth factor-B combination gene therapy prolongs angiogenic effects via recruitment of interstitial mononuclear cells and paracrine effects rather than improved pericyte coverage of angiogenic vessels. Circ Res 2008, 103:1092-1099.
12. Arsic N., Zentilin L., Zacchigna S., Santoro D., Stanta G., Salvi A., Sinagra G., Giacca M. Induction of functional neovascularization by combined VEGF and angiopoietin-1 gene transfer using AAV vectors. Mol Ther 2003, 7:450-459.
13. Pajusola K., Kunnapuu J., Vuorikoski S., Soronen J., Andre H., Pereira T., Korpisalo P., Yla-Herttuala S., Poellinger L., Alitalo K. Stabilized HIF-1alpha is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer. FASEB J 2005, 19:1365-1367.
14. Rajagopalan S., Olin J., Deitcher S., Pieczek A., Laird J., Grossman P.M., Goldman C.K., McEllin K., Kelly R., Chronos N. Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. Circulation 2007, 115:1234-1243.
15. Wirth T., Hedman M., Makinen K., Manninen H., Immonen A., Vapalahti M., Yla-Herttuala S. Safety profile of plasmid/liposomes and virus vectors in clinical gene therapy. Curr Drug Saf 2006, 1:253-257.
16. Hedman M., Hartikainen J., Syvanne M., Stjernvall J., Hedman A., Kivela A., Vanninen E., Mussalo H., Kauppila E., Simula S., et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003, 107:2677-2683.
17. Hedman M., Muona K., Hedman A., Kivela A., Syvanne M., Eranen J., Rantala A., Stjernvall J., Nieminen M.S., Hartikainen J., Yla-Herttuala S. Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Ther 2009, 16:629-634.
18. Gupta R., Tongers J., Losordo D.W. Human studies of angiogenic gene therapy. Circ Res 2009, 105:724-736.
19. Rajagopalan S., Mohler E.R., Lederman R.J., Mendelsohn F.O., Saucedo J.F., Goldman C.K., Blebea J., Macko J., Kessler P.D., Rasmussen H.S., Annex B.H. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003, 108:1933-1938.
20. Rissanen T.T., Korpisalo P., Karvinen H., Liimatainen T., Laidinen S., Grohn O.H., Yla-Herttuala S. High-resolution ultrasound perfusion imaging of therapeutic angiogenesis. JACC Cardiovasc Imaging 2008, 1:83-91.
21. Korpisalo P., Rissanen T.T., Bengtsson T., Liimatainen T., Laidinen S., Karvinen H., Markkanen J.E., Grohn O.H., Yla-Herttuala S. Therapeutic angiogenesis with placental growth factor improves exercise tolerance of ischaemic rabbit hindlimbs. Cardiovasc Res 2008, 80:263-270.